Solventum 10-Q: Q3 Swings to $12M Net Loss; Nine-Month Operating Cash Flow Slips to $215M
SOLV sits 30% above its 52-week low of $62.38 on elevated volume (1.8× avg).
Summary
Solventum's Q3 10-Q shows a $12 million net loss against last year's gain-inflated $1,266 million profit, nine-month operating cash flow of $215 million, and a litigation accrual that jumped to $234 million. It also details new 3M supply agreements running to 2036 with minimum purchase obligations.
Key Events · Earnings and Guidance · SOLV
-
Q3 Swings to $12M Net Loss
Third-quarter 2026 net loss was $12 million, or $(0.07) per diluted share, versus net income of $1,266 million ($7.22) a year earlier, which included a $1,518 million gain on the Purification and Filtration sale. Operating income fell to $68 million from $1,690 million.
-
Cash Flow and Balance Sheet Tighten
Nine-month operating cash flow was $215 million versus $274 million, and cash and cash equivalents fell to $451 million from $878 million at December 31, 2025. Total debt stood at $5,068 million, including $507 million of short-term borrowings and current maturities.
-
Litigation Accrual Jumps to $234M
Accrued litigation costs rose to $234 million from $31 million at year-end after $204 million of legal charges in the nine months, driven by the Bair Hugger matter. The company says it cannot estimate a possible loss above the recorded liability.
-
Buybacks Consume $403M
Solventum repurchased 5.3 million shares for $403 million in the nine months under the $1 billion program approved in November 2025, leaving roughly $597 million of authorization.
Analysis · SOLV · Industrial Applications And Services
The 10-Q fills in the numbers behind the same-day Q3 8-K, and the headline is that GAAP results look nothing like last year: a $12 million net loss versus $1,266 million of net income in Q3 2025, which had been inflated by the $1,518 million gain on the Purification and Filtration sale. Operating income fell to $68 million from $1,690 million on the same comparison. More useful for the thesis is the cash picture: nine-month operating cash flow of $215 million versus $274 million, cash down to $451 million from $878 million at year-end, and $403 million spent on buybacks. Accrued litigation rose to $234 million from $31 million after $204 million of charges, mostly the Bair Hugger matter, so legal costs remain a live call on cash. The new 3M supply amendments lock in a decade-long term to 2036 with minimum purchase obligations and 3% annual price escalators, which adds cost visibility but also a committed floor. With the Health Information Systems separation review still open, this filing is the baseline investors will judge that decision against.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SOLV was trading at $81.05 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $14.8B. The 52-week trading range was $62.38 to $94.16. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.